Media Thread, page-15632

IMO a huge step forward for CHM and IMU as CHM / Hopper is about to challenge current SOC rules

Today CHM anns:

CHIMERIC & ACHIEVE CLINICS FORM COLLABORATION
TO EXPAND THE REACH OF CHM’S CELL THERAPIES
• Chimeric Therapeutics is developing CHM CDH17, the world’s first cadherin 17-
directed CAR-T cell therapy, and is recruiting GI cancer patients to a clinical trial in the
United States (NCT06055439)
• Achieve Clinics is revolutionising the cancer patient’s journey to future cell therapies
through PRO-Aph™, a zero-cost option for patients to undergo proactive apheresis
• Chimeric and Achieve will collaborate to enable the use of product collected from
apheresis, which is cryopreserved from patients according to Achieve Clinics process,
for the manufacture of CHM CDH17
Sydney, Australia, 25 September 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the
“Company”), an Australian leader in cell therapy, is pleased to announce a partnership with
Achieve Clinics (“Achieve”), a Los Angeles, California biotechnology company dedicated to
improving patient access to autologous cell therapies.
Achieve’s PRO-Aph transforms how patients access cell therapies because they do not have to
wait until the standard of care fails them before beginning to contemplate a possible future cell
therapy option. Waiting for cancer to progress while experiencing systemic chemotherapy
complicates the logistics of the leukopheresis and renders the collected cells less likely to deliver
an effective CAR T. PRO-Aph mitigates these issues by proactively collecting patients’ cells
while they are still at their healthiest point.
“The use of patients’ cells that have previously been exposed to chemotherapy and the logistical
challenges of just-in-time manufacturing have a negative impact both on patientstrying to access
these new medicines and cell therapy companies working to advance their clinical programs,”
said Jason B Litten MD, Chief Medical Officer of Chimeric. “We believe Achieve’s revolutionary
approach will streamline our future development plans and make it easier for patients to access
CHM CDH17.”
“Achieve is excited to support Chimeric’s clinical trial, especially given that it is one of the only
CAR Ts with IND clearance in advanced gastrointestinal cancers,” said Brad Heller, PhD, Chief
Executive Officer of Achieve Clinics. “Advanced GI cancer patients are prone to bleeding issues
that make apheresis risky, so being able to support this patient population early in their cancer
treatment is especially meaningful. We are excited to help more patients gain easier access to
CHM CDH17, while improving accrual rates and development timelines.”
Under the collaboration, Achieve Clinics will perform PRO-Aph proactive collection and storage
of autologous cell therapy starting material from appropriately consented patients with
gastrointestinal cancer or other applicable diagnoses. Collected patients will become part of
Achieve’s PRO-Aph participant registry from which Chimeric may screen and enrol patients
once eligible. Collected cells will then be used to manufacture CHM CDH17 for eligible patients.
Any unused patient cells can be used for future research purposes.